胆囊癌诊断及治疗研究进展

甘 玉林1, 王宏 宾*2
1、青海大学研究生院;青海大学附属医院
2、青海大学附属医院

摘要


胆囊癌是一种起源于胆囊黏膜的恶性消化系统肿瘤，具有隐匿性、易侵袭转移、早期诊断难、预后差、死亡率高等特点，早期的诊断及对症治疗尤为重要。胆囊癌人群中发病率虽低，但恶性程度极高，胆囊癌患者早期一般没有明显的临床表现，大部分患者就诊时已为中晚期，失去手术机会。近年来，各种胆囊癌相关的影像学检查、实验室检查以及包括手术和放化疗在内的诊治手段的临床应用大大提高了胆囊癌患者的生存率，改善了患者预后。本文就当前胆囊癌诊断和治疗方面的最新研究进展做一综述，为临床中对胆囊癌的诊断及治疗提供相应参考。

关键词


胆囊癌；影像学检查；实验室检查；手术治疗；放化疗；免疫治疗

全文:

PDF


参考


[1]ROA J C, GARCÍA P, KAPOOR V K, et al. Gallbladder cancer [J]. Nat Rev Dis Primers, 2022, 8(1): 69.

[2]Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol, 2014, 6: 99-109.

[3]邹声泉，张林.全国胆囊癌临床流行病学调查报告[J].中国实用外科杂志，2000，20（1）：43-46

[4]任泰，李永盛，耿亚军，等.中国2010-2017年胆囊癌治疗模式及预后分析[J].中华外科杂志，2020，58（9）：E008.

[5]孙旭恒，王一钧，张薇，等.中国胆囊癌流行病学特征与诊治及预后分析（附6159例报告）[J].中华消化外科杂志，2022，21（1）：114-128.

[6]Badea R, Zaro R, Opincariu I, et al. Ultrasound in the examination of the gallbladder - a holistic approach: grey scale, Doppler, CEUS, elastography, and 3D[J]. Med Ultrason, 2014, 16(4): 345-355.

[7]Miller G, Jarnagrn WR. Gallbladdercarcinoma[J].European Journal of Surgical Oncology, 2008, 34(3): 306-312.

[8]Zhang HP, Bai M, Gu JY, et al. Value of contrast-enhanced ultrasound in the diあerential diagnosis of gallbladder lesion[J].World J Gastroenterol, 2018, 24(6): 744-751.

[9]Song ER, Chung WS, et al.CT differentiation of 1-2-cm gallbladderpolyps : benign vs malignant[J].Dig Dis Sci, 2014, 59(8): 1917-1924.

[10]Ramachandran A, Srivastava DN, Madhusudhan KS. Gallbladder cancer revisited: the evolving role of a radiologist[J]. Br J Radiol, 2021, 94(1117): 20200726.

[11]Ohtani T, Shirai Y, Tsukada K, et al. Spread of gallbladder carcinoma: CT evaluation with pathologic correlation[J]. Abdom Imaging, 1996, 21(3): 195-201.

[12]Kalra N, Gupta P, Singhal M, et al. Cross-sectional imaging of gallbladder carcinoma: an update[J]. J Clin Exp Hepatol, 2019, 9(3): 334-344.

[13]Schwartz LH, Black J, Fong Y, et al. Gallbladder carcinoma: findings at MR imaging with MR cholangiopancreatography[J]. J Comput Assist Tomogr, 2002, 26(3): 405-410.

[14]Albazaz R, Patel CN, Chowdhury FU, et al. Clinical impact of FDG PET-CT on management decisions for patients with primary biliary tumours[J]. Insights Imaging, 2013, 4(5): 691-700.

[15]吴平，周克，陈治明，等.18F氟代脱氧葡萄糖正电子发射断层成像术/计算机断层扫描显像在胆囊癌中的诊断价值[J].实用医技杂志，2014，21（2）131-135.

[16]Fogel EL, DeBellis M, McHenry L, et al. Eあectiveness of a new long cytology brush in the evaluation of malignant biliary obstruction: a prospective study[J]. Gastrointest Endosc, 2006, 63(1): 71-77.

[17]Hijioka S, Hara K, Mizuno N, et al. Diagnostic yield of endoscopic retrograde cholangiography and of EUS-guided fine needle aspiration sampling in gallbladder carcinomas[J]. J Hepatobiliary Pancreat Sci, 2012, 19(6): 650-655.

[18]Shotton R, Lamarca A, Valle J, et al. Potential utility of liquid biopsies in the management of patients with biliary tract cancers: a review[J]. World J Gastrointest Oncol, 2021, 13(9): 1073-1085.

[19]王楚风，蒋安.原发性肝癌的分子诊断[J/OL].中华肝脏外科手术学电子杂志，2023，12（5）：499-503.

[20]Macias RIR, Banales JM, Sangro B, et al. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma[J].Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1468-1477.

[21]Wang YF, Feng FL, Zhao XH, et al. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer[J]. World J Gastroenterol, 2014, 20(14): 4085-4092.

[22]Spinelli A, Schumacher G, Pascher A, et al. Extended surgical resection for xanthogranulomatous cholecystitis mimicking advanced gallbladder carcinoma: a case report and review of literature[J].World J Gastroenterol, 2006, 12(14): 2293-2296.

[23]Marrelli D, Caruso S, Pedrazzani C, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions[J]. Am J Surg, 2009, 198(3): 333-339.

[24]Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9-tumor marker: past, present, and future[J]. World J Gastrointest Surg, 2020, 12(12): 468-490.

[25]Wang YF, Feng FL, Zhao XH et al. Combined detection tumor markers for diagnosis and prognosis of gallbladder canc-er[J].World Journal of Gastroenterol, 2014, 20(14): 4085-4092.

[26]Branch of Biliary Surgery, Chinese Surgical Society; Chinese Com-mittee of Biliary Surgeons. Guideline for the diagnosis and treatment of gallbladder carcinoma (2019 edition)[J]. Chin J Surg, 2020, 58(4): 243-251. DOI: 10.3760/cma.j.cn112139-20200106-00014.中华医学会外科学分会胆道外科学组，中国医师协会外科医师分会胆道外科专业委员会.胆囊癌诊断和治疗指南（2019版）[J].中华外科杂志，2020，58（4）：243-251. DOI：10.3760/cma.j.cn112139-20200106-00014.

[27]LEE SE, KIM KS, KIM WB, et al. Practical guidelines for the surgical treatment of gallbladder cancer[J]. J Korean Med Sci, 2014, 29(10): 1333-1340. DOI: 10.3346/jkms.2014.29.10.1333.

[28]LEE W, JEONG CY, JANG JY, et al. Do hepatic-sided tumors re-quire more extensive resection than peritoneal-sided tumors in pa-tients with T2 gallbladder cancer? Results of a retrospective multi-center study[J]. Surgery, 2017, 162(3): 515-524. DOI: 10.1016/j.surg.2017.05.004.

[29]BENSON AB, D’ANGELICA MI, ABBOTT DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5): 541-565. DOI: 10.6004/jnccn.2021.0022.

[30]CHIBA N, SHIMAZU M, OCHIAI S, et al. Resection of hepatic lesions perfused by the cholecystic vein using indocyanine green navigation in patients with cT2 gallbladder cancer[J]. World J Surg, 2019, 43(2): 608-614. DOI: 10.1007/s00268-018-4810-8.

[31]ALOIA TA, JÁRUFE N, JAVLE M, et al. Gallbladder cancer: Expert consensus statement[J]. HPB (Oxford), 2015, 17(8): 681-690. DOI: 10.1111/hpb.12444.

[32]NIGRI G, BERARDI G, MATTANA C, et al. Routine extra-hepatic bile duct resection in gallbladder cancer patients without bile duct infiltration: A systematic review[J]. Surgeon, 2016, 14(6): 337-344. DOI: 10.1016/j.surge.2016.06.004.

[33]OKUSAKAT, NAKACHIK, FUKUTOMIA, et al. Gemcitabine alone or incombination with cisplatin in patients with biliary tract cancer: A comparative multicentre study in Japan[J].BrJ Cancer, 2010, 103(4): 469-474.

[34]KATO A, SHIMIZU H, OHTSUKA M, et al. Surgical resection after downsizing chemother-apy for initially unresectable locally advanced biliary tract cancer: A retrospective single-center study[J].AnnSurg Oncol, 2013, 20(1): 318-324.

[35]DE ARETXABALA X, ROAI, BERRIOS M, et al.Chemoradiotherapy in gallbladder cancer [J].JSurgOncol, 2006, 93(8): 699-704.

[36]ENGINEER R, GOEL M, CHOPRA S, et al.Neoadjuvant chemoradiation followed by surGery for locally advanced gallbladder cancers: A new paradigm[J].AnnSurg Oncol, 2016, 23(9): 3009-3015

[37]FRANCISCO L M, SALINAS V H, BROWN K E, et al.PD-L1 regulates the development, maintenance, and function of induced regulato Ry T cells[J].JExpMed, 2009, 206(13): 3015-3129

[38]JAKUBOWSKI C D, AZAD N S.Immune checkpoint inhibitor therapyin biliarytract cancer (cholangiocarcinoma)[J].Chin Clin Oncol, 2020, 9(1): 2

[39]李起，陈晨，张瑞，等.微卫星不稳定性与胆囊癌诊断和治疗研究进展[J].中华消化外科杂志2019，（11）：1082-1086

[40]LE D T, URAM J N, WANG H, et al.PD-1 Blockade in tumors with mismatch-repair deficiency[J].N Engl J Med, 2015, 372(26): 2509-2520.

[41]PIHA-PAULSA, OH D Y, UENO M, et al.Efficacy and safety of pembrolizumab for the Treatment of advanced biliary cancer: Results From the KEYNOTE-158 and KEYNOTE-028 studies[J].Int J Cancer, 2020, 147(8): 2190-2198

[42]KIM R D, CHUNG V, ALESE O B, et al.A Phase 2 multi-institutional study of nivolumab For patients with advanced refractory biliary Tract cancer[J].JAMA Oncol, 2020, 6(6): 888-894.

[43]SUND, MAJ, WANGJ, et al. Anti-PD-1ther Apy combined with chemotherapy in patients With advanced biliary tract cancer[J].Cancer Immunol Immunother, 2019, 68(9): 1527-1535.


Refbacks

  • 当前没有refback。